Evidence of cartilaginous benefit of treatment with infliximab in rheumatoid arthritis using measurement of serum COMP

• YAMAMOTO Motohisa

  First Department of Internal Medicine, Sapporo Medical University School of Medicine

• TAKAHASHI Hiroki

  First Department of Internal Medicine, Sapporo Medical University School of Medicine

• OHARA Mikiko

  First Department of Internal Medicine, Sapporo Medical University School of Medicine

• SUZUKI Chisako

  First Department of Internal Medicine, Sapporo Medical University School of Medicine

• NAISHIRO Yasuyoshi

  First Department of Internal Medicine, Sapporo Medical University School of Medicine

• YAMAMOTO Hiroyuki

  First Department of Internal Medicine, Sapporo Medical University School of Medicine

• SHINOMURA Yasuhisa

  First Department of Internal Medicine, Sapporo Medical University School of Medicine

• IMAI Kohzoh

  Sapporo Medical University

Bibliographic Information

Other Title

• 関節リウマチに対するインフリキシマブの血清ＣＯＭＰ濃度測定を用いた軟骨破壊抑制効果の解析

Abstract

  Recently, it has become possible to measure the concentration of serum cartilage oligomeric matrix protein (COMP) in various arthritis, and it is expected to be a novel biomarker indicative of cartilage destruction. In this study, we evaluated the diagnostic effectiveness of serum COMP in rheumatic diseases and analyzed the inhibition of cartilage destruction in patients with rheumatoid arthritis who were prescribed with infliximab (IFX) for one year. The changes in the concentration of serum COMP and the joint narrow space of Sharp score (ΔSharp-JNS) were evaluated. The level of serum COMP decreased from 23.04±7.14 U/l to 8.69±2.89 U/l (p<0.005) and improved ΔSharp-JNS (−0.50±6.38 points). We believed that these results were influenced by the effects of methotrexate (MTX) that was prescribed together with IFX, and we analyzed the group that was administered only MTX therapy as a reference. However, the serum COMP concentration and Sharp-JNS in the MTX group did not decrease. The serological and radiological results revealed that IFX inhibited cartilage destruction, and it is possible that serum COMP is one of the novel biomarkers in RA patients treated with anti-tumor necrosis factor-α antibody therapy.<br>

Journal

• Japanese Journal of Clinical Immunology

  Japanese Journal of Clinical Immunology 30 (1), 41-47, 2007

  The Japan Society for Clinical Immunology

Keywords

• cartilage oligomeric matrix protein (COMP)
• infliximab, methotrexate
• rheumatoid arthritis
• Sharp score

Details

• CRID: 1390282679626529792
• NII Article ID: 10018858082
• NII Book ID: AN00357971
• DOI: 10.2177/jsci.30.41
• ISSN: 13497413
• ISSN: 09114300
• Web Site: http://www.jstage.jst.go.jp/article/jsci/30/1/30_1_41/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2007179174
• Text Lang: ja
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed